TECHWIRE 30
(CIX: WRAL30)  921.91  up arrow+4.39  (0.48 %)  Updated: 08:10 PM EDT, Jun 18 2013
(NQ: Apple)  431.77  down arrow-0.23  (-0.05 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NY: Quintiles)  43.89  up arrow+0.36  (0.83 %)  Updated: 06:40 PM EDT, Jun 18 2013
(OP: BASF SE)  99.86  up arrow+1.6  (1.63 %)  Updated: 08:10 PM EDT, Jun 18 2013
(NQ: BioCryst)  1.79  up arrow+0.09  (5.29 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: BioDelivery)  4.66  up arrow+0.22  (4.96 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: CEMP)  7.13  up arrow+0.01  (0.14 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: Cisco Systems)  24.82  up arrow+0.12  (0.49 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: Cornerstone)  8.45  down arrow-0.16  (-1.86 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: Cree)  65.70  up arrow+2.77  (4.4 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: DARA)  0.69  down arrow-0.01  (-0.72 %)  Updated: 03:59 PM EDT, Jun 18 2013
(NY: EMC Corp.)  24.99  up arrow+0.16  (0.64 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NQ: Extreme Networks)  3.55    (0 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: Facebook)  24.21  up arrow+0.19  (0.78 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NY: GlaxoSmithKline)  52.47  down arrow-0.27  (-0.51 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NQ: Google)  900.62  up arrow+14.37  (1.62 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NY: IBM)  204.87  up arrow+1.83  (0.9 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NY: LH)  100.78  up arrow+0.34  (0.34 %)  Updated: 06:40 PM EDT, Jun 18 2013
(OP: Lenovo Group)  19.14  down arrow-0.13  (-0.67 %)  Updated: 08:10 PM EDT, Jun 18 2013
(NY: MRK)  47.75  down arrow-0.05  (-0.1 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NQ: Microsoft Corp)  34.98  down arrow-0.02  (-0.06 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: NetApp)  39.39  up arrow+0.78  (2.02 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NY: Novartis AG ADS)  73.12  down arrow-0.17  (-0.23 %)  Updated: 06:40 PM EDT, Jun 18 2013
(OP: Novozymes A/S)  34.71  up arrow+0.7  (2.06 %)  Updated: 08:10 PM EDT, Jun 18 2013
(NY: Pfizer)  29.40  up arrow+0.24  (0.82 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NQ: Pozen)  5.12  up arrow+0.09  (1.79 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NY: Red Hat)  46.63  up arrow+0.95  (2.08 %)  Updated: 06:40 PM EDT, Jun 18 2013
(NQ: BBRY)  14.84  up arrow+0.54  (3.78 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: Salix)  66.83  up arrow+0.62  (0.94 %)  Updated: 04:00 PM EDT, Jun 18 2013
(NQ: SQI)  23.58  up arrow+0.34  (1.46 %)  Updated: 04:00 PM EDT, Jun 18 2013

Posts tagged “Pozen”

May 29

Safer aspirin from Pozen accepted for FDA review

Pozen An FDA approval decision on Pozen's PA drug could come by early January.

Updated May 8

Premium Lock AstraZeneca's decision to stop pain drug's promotion leaves Pozen considering new partners

AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?

How Vimovo works How Vimovo works

May 8

Premium Lock Pozen's painful partner news triggers 15% drop in stock price

Pozen Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?

Updated May 8

Premium Lock Latest pain for Pozen: AstraZeneca to stop sales of its pain reliever in US

Pozen The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?

March 27

Premium Lock Safer aspirin from Pozen filed for FDA approval

FDA A safer-on-the-stomach aspirin developed by Pozen has been submitted to the Food and Drug Administration for regulatory approval

Updated March 12

Premium Lock Pozen's drug combination patent maintained in Europe

Pozen CEO John Plachetka European patents for Pozen's combination drug technology are valid and will continue to stand, according to a decision issued by European patent authorities.

March 6

Premium Lock Pozen pain reliever sales, royalties surge in 2012

Pozen Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

November 7, 2012

Premium Lock Pozen reports positive test results for proposed aspirin therapy

Pozen Results from two Phase 3 clinical trials for its proposed aspirin therapy are positive, Chapel Hill-based Pozen says.

October 2, 2012

Premium Lock Pozen prevails in patent fight over pain killer

Treixmet The Chapel Hill-based pharmaceutical firm has already sold future royalty rights and milestone payments that it would have received from GlaxoSmithKline for $75 million.

August 24, 2012

Premium Lock Pozen won't need new trial for proposed safer aspirin

Pozen's headaches After discussions with the FDA, the Chapel Hill-based drug firm says its safer form of aspirin could be ready for a drug filing in the first half of 2013.

June 21, 2012

Premium Lock FDA wants more tests on proposed Pozen heart drug

FDA The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.

May 8, 2012

Premium Lock Pozen migraine drug licensed to Desitin for commercialization in Europe

Pozen The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.

May 1, 2012

Premium Lock Pozen losses increase but arthritis drug royalties grow

Pozen The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.

April 30, 2012

Premium Lock Pozen runs into a headache with FDA over safer aspirin

Pozen's headache During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose

Updated March 22, 2012

Premium Lock Pozen shares surge on aspirin therapy trial news

The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

December 22, 2011

Premium Lock Pozen strikes manufacturing pact with Patheon for heart drug

Patheon logo Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.

November 28, 2011

Premium Lock Pozen's $75M deal - It's all about cash for product pipeline

Treixmet The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka

Updated November 28, 2011

Premium Lock Pozen sells royalty rights to migraine drug for $75M

Treixmet Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Jim Roberts
Entrepreneurship
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll

Videos

 
  • Allscripts bringing hundreds of jobs…

  • Nonprofit to handle NC economic…

  • Raleigh goes green, saves green with…

  • Gov. Pat McCrory speaks to NC Chamber

  • NC business leaders unveil job growth…

  • Investment expert: Leading is key in…

  • Retailers tout deals on Twitter

  • Vision for RTP: Social centerpiece